Why the study?
Despite standard antihypertensive therapies, many patients with CKD, heart failure, obesity, and diabetes fail to achieve recommended blood pressure targets.
Do SGLT2 inhibitors lower blood pressure in high-risk individuals with and without diabetes?
Do SGLT2 inhibitors lower blood pressure in high-risk individuals with and without diabetes?
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors have modest antihypertensive properties and may serve as an adjunctive blood pressure-lowering therapy in high-risk patients.
Hypertension is a well-established risk factor for cardiovascular (CV) events in patients with chronic kidney disease (CKD), heart failure, obesity, and diabetes. Despite the usual prescribed antihypertensive therapies, many patients fail to achieve the recommended blood pressure (BP) targets.This review summarizes the clinical BP-lowering data presented in major CV and kidney outcome trials for sodium-glucose cotransporter-2 (SGLT2) inhibitors, as well as smaller dedicated BP trials in high-risk individuals with and without diabetes. We have also highlighted potential mechanisms that may contribute to the antihypertensive effects of SGLT2 inhibitors, including natriuresis and hemodynamic changes, a loop diuretic-like effect, and alterations in vascular physiology.The antihypertensive properties of SGLT2 inhibitors are generally modest but may be larger in certain patient populations. SGLT2 inhibitors may have an additional role as an adjunctive BP-lowering therapy in patients with hypertension at high risk of CV disease or kidney disease.
No takes yet. Share an insight, caveat, or question.
Kugathasan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: